Monthly Prescribing Reference

Descovy for PrEP Continues to Be Noninferior to Truvada, According to 96 Week Data

Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points. In the phase 3, ...
Nasdaq

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 ...
NBC News

FDA approves Gilead's next-generation HIV PrEP pill, Descovy

Gilead Sciences, the drug giant behind the blockbuster HIV prevention pill Truvada, won FDA approval on Thursday to market Descovy — a medication already used by those who have HIV — as its ...
FiercePharma

Gilead's Descovy nabs PrEP nod. Next step: Convert Truvada patients before generics hit

Clock’s ticking. After an expected FDA nod for Descovy as the second HIV PrEP drug, Gilead Sciences now has one year to convince its current Truvada takers to switch over before generics hit. The FDA ...
Monthly Prescribing Reference

Descovy for HIV-1 PrEP Gets FDA Approval

The FDA has approved Descovy for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at-risk ...
Business Wire

Gilead Canada Announces Notice of Compliance for DESCOVY® (emtricitabine, tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for DESCOVY® (emtricitabine 200 mg and ...
Medscape

One in Six HIV PrEP Descovy Switches May Be Unnecessary

George Froehle, PA, a primary care clinician at CentraCare in rural St. Cloud, Minnesota, has been prescribing the HIV prevention pill tenofovir disoproxil fumarate plus emtracitabine (TDF/FTC) since ...
Nasdaq

Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations

BOSTON--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today presented longer-term results from the DISCOVER trial of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, ...
Slate

Your PrEP Is Not a Status Symbol

This post is part of Outward, Slate’s home for coverage of LGBTQ life, thought, and culture. Read more here. In October, the U.S. Food and Drug Administration approved the drug Descovy to be used as a ...
FiercePharma

Gilead's Descovy AdCom gets 'controversial' as panelists split over PrEP use in women

As expected, Gilead’s Descovy had no problem securing backing from an FDA panel of experts for HIV prevention in men and transgender women. But beyond that, it ran into some issues. On Wednesday, an ...
Business Insider

Gilead Canada Announces Notice of Compliance for DESCOVY® (emtricitabine, tenofovir alafenamide) for HIV Pre-exposure Prophylaxis (PrEP)

-- PrEP is part of the ongoing efforts by Gilead Canada to end the HIV epidemic-- MISSISSAUGA, ON, Dec. 1, 2020 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada ...